It is also important in treating mood disorders
Last Published 07.01.2026 Effective Date: 07.01.2026 This policy addresses the use of tocilizumab injection for intravenous infusion for the treatment of polyarticular juvenile idiopathic arthritis, rheumatoid arthritis, systemic juvenile idiopathic arthritis, giant cell arteritis, cytokine release syndrome, acute graft-versus-host disease, and immune checkpoint inhibitor-related toxicities
Laboratory Monitoring Depending on your medical history and treatment goals, your provider may recommend periodic laboratory testing and clinical evaluation throughout therapy
The parenteral market will be supported by widespread clinical familiarity with injectable formulations, strong preference among physicians for parenteral delivery for optimal absorption and efficacy, rising patient acceptance of weekly injection options, increasing prescriptions for advanced diabetes cases requiring reliable bioavailability, expanding adoption in hospital and clinic-based chronic-care programs and rising use among patients who struggle to adhere to oral regimens
